Mostrar el registro sencillo del ítem
Cancer immunotherapy as a new treatment option
| dc.contributor.author | Burgos-Molina, Antonio Manuel | |
| dc.contributor.author | Padín-López, Alba | |
| dc.contributor.author | Alonso-Ortiz, Antonio | |
| dc.date.accessioned | 2019-01-16T12:46:39Z | |
| dc.date.available | 2019-01-16T12:46:39Z | |
| dc.date.created | 2018 | |
| dc.date.issued | 2019-01-16 | |
| dc.identifier.uri | https://hdl.handle.net/10630/17165 | |
| dc.description.abstract | Cancer can coaptate the immune control of the immune system (IS), evade immunity and its destruction. So, could we say openly that immunotherapy is a viable treatment option for patients with advanced cancer? Yes, immunotherapy would give us great advances in the war against cancer. Therefore, the development of a new generation of immune modulators (which have been analyzed in the following article) is necessary. In addition, these will be more effective if we use them in combination, taking advantage of their synergy. | en_US |
| dc.description.sponsorship | Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech. | en_US |
| dc.language.iso | eng | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | Cancer - Tratamiento | en_US |
| dc.subject.other | Cancer inmunotherapy | en_US |
| dc.subject.other | New treatment option | en_US |
| dc.title | Cancer immunotherapy as a new treatment option | en_US |
| dc.type | info:eu-repo/semantics/conferenceObject | en_US |
| dc.centro | Facultad de Medicina | en_US |
| dc.relation.eventtitle | 16th ASEICA International Congress 2018 | en_US |
| dc.relation.eventplace | Valencia (España) | en_US |
| dc.relation.eventdate | 06-08/11/2018 | en_US |
| dc.rights.cc | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional